Can-Fite BioPharma
About Science Pipeline Investor Information Contact Us

Investor Information

Investor Information

Investor Information

Company Information

Can-Fite BioPharma Ltd. (NYSE American: CANF)

Can-Fite BioPharma Ltd. is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company's lead drug candidate, Piclidenoson, is scheduled to enter Phase III trials in 2017 for two indications, rheumatoid arthritis and psoriasis. The rheumatoid arthritis Phase III protocol has recently been agreed with the European Medicines Agency. Can-Fite's liver cancer drug Namodenoson is in Phase II trials for patients with liver cancer and is slated to enter Phase II for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for hepatocellular carcinoma by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction in preclinical studies and is being prepared for an IND submission to the FDA and a Phase I trial. These drugs have an excellent safety profile with experience in over 1,000 patients in clinical studies to date.

Stock Information


Last Change Volume

Can-Fite's ADRs trade in the USA under the ticker CANFY and the ordinary shares trade on the Tel-Aviv Stock Exchange under the ticker CFBI.

More on CFBI »

Investor Relations

Corporate ProfileĀ®
Laurel Moody
646 810 0608

Quick Links

Recent News